Quotes 5-day view Delayed Nyse
06/14/2021
06/15/2021
06/16/2021
06/17/2021
06/18/2021
Date
47.42(c)
47.69(c)
48.03(c)
46.77(c)
47.12(c)
Last
724 936
558 074
611 416
993 721
837 483
Volume
-0.94% +0.57% +0.71% -2.62% +0.75% Change
Sales 2021
2 265 M - -
Net income 2021
492 M - -
Net Debt 2021
887 M - -
P/E ratio 2021
21,8x
Yield 2021
-
Sales 2022
2 198 M - -
Net income 2022
455 M - -
Net Debt 2022
453 M - -
P/E ratio 2022
23,9x
Yield 2022
-
Capitalization
10 763 M 10 763 M -
EV / Sales 2021
5,14x
EV / Sales 2022
5,10x
Nbr of Employees
5 750
Free-Float
98,2%
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or...
All news about QIAGEN N.V.
06/17 QIAGEN NV : Deutsche Bank reiterates its Buy ratingMD
06/15 QIAGEN N : Shareholder Davidson Kempner European Partners To Vote Against Chair..MT
06/11 QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..EQ
06/11 DGAP-PVR : QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG ..DJ
06/11 Today on Wall Street : Much ado about nothing06/11 ANALYST RECOMMENDATIONS : Brown-Forman, Casey's General Stores, GameStop, Reckit..06/11 QIAGEN NV : Berenberg reaffirms its Buy ratingMD
06/09 ANALYST RECOMMENDATIONS : APA, Bank of America, Citigroup, Goldman Sachs, Visa....06/08 QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..EQ
06/08 DGAP-PVR : QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [..DJ
06/08 QIAGEN NV : Goldman Sachs gives a Buy ratingMD
06/07 PRESS RELEASE : Innovative Molecules raises EUR20 million Series A equity financ..DJ
06/03 QIAGEN N : Goldman Sachs Starts Qiagen NV at Neutral With $52 Price TargetMT
06/03 QIAGEN NV : Goldman Sachs remains NeutralMD
06/03 QIAGEN NV : Gets a Neutral rating from JefferiesMD
News in other languages on QIAGEN N.V.
Analyst Recommendations on QIAGEN N.V.
QIAGEN N : first-quarter profit tops expectations on growth in non-COVID-19 products
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends QIAGEN N.V.
Short Term Mid-Term Long Term Trends Neutral Neutral Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
14
Average target price
57,46 $
Last Close Price
47,12 $
Spread / Highest target
52,8%
Spread / Average Target
21,9%
Spread / Lowest Target
-13,0%
Please enable JavaScript in your browser's settings to use dynamic charts.
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
